Intercept Pharmaceuticals (ICPT)- Barbara Gayle Duncan, Chief Accounting Officer, sold 146 shares at $145.11. Duncan still owns 30,808 shares of ICPT. David Shapiro, CMO and EVO-Development, sold 163 shares at $145.11. Shapiro still owns 48,391 shares of ICPT. Mark Pruzanski, President & CEO, sold 714 shares at $145.11. Pruzanski still owns 547,566 shares of ICPT. Rachel McMinn, Chief Strategy Officer, sold 106 shares at $145.11. McMinn still owns 13,986 shares of ICPT.
Seattle Genetics (SGEN)- Clay B. Siegall, President & CEO, sold 7,618 shares at $40.56. The total value of the transaction was $308,999. Siegall still owns 556,115 shares of SGEN.
MediciNova (MNOV)- Geoffrey O’Brien, Vice President, sold 3,300 shares at $8. The total value of the transaction was $26,400. O’Brien still owns 5,000 shares of MNOV.
ImmuCell (ICCC)- Joseph H. Crabb, VP & Chief Scientific Officer, sold 2,691 shares in two separate transactions. Crabb sold 2,426 shares at $6.59; and 265 shares at $6.54. Crabb still owns 107,046 shares of ICCC.
Akebia Therapeutics (AKBA)- Duane Nash, Director, sold 1,980 shares at $7.48. The total value of the transaction was $14,819. Nash still owns 26,629 shares of AKBA.
Gilead Sciences (GILD)- John F. Milligan, President & CEO, sold 112,000 shares at $84.33. The total value of the transaction was approximately $9.44 million. Milligan still owns 1,058,963 shares of GILD.